Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$80.92M-9.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Honroth
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 632
- Beta
- 0.28
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.42
Financials
Revenue
$80.92M-9.1%Net Income
$-7.10M-151.7%EBITDA
$-1.71M-108.0%Free Cash Flow
$-15.71M-215.7%EPS (diluted)
$-0.17-145.9%Shares Outstanding (diluted)
42.02M+13.1%Operating Expenses
$50.43MCash & Debt
$33.97MReturn of Capital
$1.28MRevenue by Segment (annual)
$303.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $320.17M | $-36.74M | $-0.88 |
| 2025 | $292.50M | $-33.99M | $-0.83 |
| 2024 | $303.91M | $-184.35M | $-4.59 |
| 2023 | $338.75M | $-52.44M | $-1.33 |
| 2022 | $316.22M | $-26.55M | $-0.68 |
| 2021 | $291.01M | $-31.55M | $-0.82 |
| 2020 | $264.16M | $-166.79M | $-4.37 |
| 2019 | $359.48M | $61.34M | $1.64 |
| 2018 | $344.29M | $16.34M | $0.44 |
| 2017 | $349.64M | $-7.05M | $-0.19 |
| 2016 | $353.69M | $-43.59M | $-1.23 |
| 2015 | $356.97M | $-3.39M | $-0.09 |
| 2014 | $354.45M | $2.35M | $0.09 |
| 2013 | $342.03M | $-1.21M | $-0.02 |
Valuation
ANGOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (14)
- Newszacks.com·9d ago·Positive
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures.
View source ↗ - Newsbusinesswire.com·16d ago·Positive
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as …
View source ↗ - Newsseekingalpha.com·38d ago·Neutral
…nd Margin Concerns Persist AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.
View source ↗ - Newszacks.com·44d ago·Positive
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
View source ↗ - Newsbenzinga.com·45d ago·Negative
AngioDynamics Stock Is Falling Thursday: What's Going On? AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·45d ago·Neutral
AngioDynamics Q1 Earnings Call Highlights AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.
View source ↗ - Newszacks.com·45d ago·Negative
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
View source ↗ - Newsbusinesswire.com·45d ago·Positive
…l Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 20…
View source ↗ - Newsbusinesswire.com·45d ago·Positive
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effe…
View source ↗ - Newsbusinesswire.com·51d ago·Positive
…cobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research…
View source ↗ - Newsbusinesswire.com·55d ago·Positive
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company's management will hos…
View source ↗ - Newszacks.com·101d ago·Neutral
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027 AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
View source ↗
Earnings
Wed, Jan 6(in 6 weeks)
Consensus estimate $-0.11 per share
Typical surprise +36.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 8$-0.04 vs $-0.11beat
- Tue, Jul 14$-0.07 vs $-0.11beat
- Thu, Apr 2$-0.07 vs $-0.11beat
- Tue, Jan 6$-0.15 vs $-0.10miss
- Thu, Oct 2$-0.10 vs $-0.14beat
- Tue, Jul 15$-0.03 vs $-0.13beat
Estimates and results for ANGO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANGO officers and directors.
- Bought
- $240k
- Sold
- $705k
4 trades
4 trades
- Trowbridge Stephen Asold
- Trowbridge Stephen Asold
- Nighan Warren Jrsold
- Weiss Lawrence Tbought
- Trowbridge Stephen Abought
- Clemmer James Cbought
- Nighan Warren Jrsold
- Nighan Warren Jrbought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Debbie Wasserman Schultzhouse · FL25 · disclosed Oct 27, 2025 (7d later)Sell$100,001 - $250,000
- Debbie Wasserman Schultzhouse · FL25 · disclosed Jul 28, 2025 (12d later)Sell$1,001 - $15,000
- Debbie Wasserman Schultzhouse · FL25 · disclosed Jul 28, 2025 (31d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
